Myriad Genetics (NASDAQ:MYGN) is a company that is developing products that detect risks of disease based on proteins found in a patient's genes. Some of their products can also determine the likelihood that a patient will respond to a drug in a certain way, ensure optimal dosing, and find the chances of disease progression or recurrence. According to the company's website, over one million patients have already benefited from their informative testing. One of the company's primary products is BRACAnalysis, a predictive medicine test that attempts to uncover a patient's risk of getting breast or ovarian cancer. It also offers COLARIS (tests for colorectal and uterine cancer) and MELARIS (tests for melanoma). Myriad Genetics was founded...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|